

You are entering a medical section of the Pfizer Landing Page. All materials here are presented for purposes of scientific exchange. They are NOT presented for any promotional purpose.

Pfizer Posters

Abstract Session 28 - Improvements in metastatic prostate cancer: Focus on imaging and treatment

Sunday, July 3

12:15–13:45 CEST

Relugolix

A0514

Sustained castration to < 20 ng/dl for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study

Tombal B

Presentation is supported by Myovant and Pfizer.

[View Presentation](#)

Enzalutamide

A0517

Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES

Stenzl A

Presentation is supported by Astellas Pharma Inc. and Pfizer.

[View Presentation](#)